TY - JOUR
T1 - Management of orbital xanthogranuloma with methotrexate
AU - Hayden, Ashley
AU - Wilson, David J.
AU - Rosenbaum, James T.
PY - 2007/4
Y1 - 2007/4
N2 - Background/aims: To evaluate the efficacy of methotrexate (MTX) treatment for the periorbital findings in adult-onset xanthogranuloma (AOX). Methods: The medical records of three patients with AOX, with and without asthma, who were treated with MTX at Oregon Health & Science University, Portland, Oregon, USA were examined. Diagnosis of AOX was made by biopsy in all patients. The patients were evaluated between February 1998 and July 2006. All patients had failed prior medical and/or surgical treatment. MTX was administered at 10-20 mg/week with folate supplementation and a course of corticosteroids. Efficacy was assessed on the basis of improvement in skin discoloration, involvement of the visual axis and patients' report of inflammation. Results: All three patients were started on MTX, but one patient discontinued treatment after 3 weeks due to nausea. With follow-up as long as 3 years, the two patients who continued treatment lost the yellow discoloration of their skin, and they reported significantly less inflammation and ptosis after treatment. Oral corticosteroids could be reduced or discontinued. Conclusions: AOX is a rare, persistent disease that commonly involves the preseptal fat. MTX is a therapeutic option for this illness.
AB - Background/aims: To evaluate the efficacy of methotrexate (MTX) treatment for the periorbital findings in adult-onset xanthogranuloma (AOX). Methods: The medical records of three patients with AOX, with and without asthma, who were treated with MTX at Oregon Health & Science University, Portland, Oregon, USA were examined. Diagnosis of AOX was made by biopsy in all patients. The patients were evaluated between February 1998 and July 2006. All patients had failed prior medical and/or surgical treatment. MTX was administered at 10-20 mg/week with folate supplementation and a course of corticosteroids. Efficacy was assessed on the basis of improvement in skin discoloration, involvement of the visual axis and patients' report of inflammation. Results: All three patients were started on MTX, but one patient discontinued treatment after 3 weeks due to nausea. With follow-up as long as 3 years, the two patients who continued treatment lost the yellow discoloration of their skin, and they reported significantly less inflammation and ptosis after treatment. Oral corticosteroids could be reduced or discontinued. Conclusions: AOX is a rare, persistent disease that commonly involves the preseptal fat. MTX is a therapeutic option for this illness.
UR - http://www.scopus.com/inward/record.url?scp=34247276459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247276459&partnerID=8YFLogxK
U2 - 10.1136/bjo.2006.109587
DO - 10.1136/bjo.2006.109587
M3 - Article
C2 - 17135338
AN - SCOPUS:34247276459
SN - 0007-1161
VL - 91
SP - 434
EP - 436
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 4
ER -